Sue Sisley, Shane Pennington
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Dr. Barbara Rothbaum discusses combining MDMA with prolonged exposure therapy for PTSD, citing theoretical and translational research supporting a synergistic mechanism of action for treatment.
Barbara Rothbaum, Lynnette A. Averill
MDMA-assisted therapy (MDMA-AT) shows promise in treating PTSD and comorbid eating disorders. A study found significant reductions in eating disorder symptoms with MDMA-AT compared to placebo in severe PTSD patients.
Adele LaFrance, Timothy Brewerton
Families of veterans are affected by trauma, depression, and addiction. Session explores healing for families impacted by veterans' struggles.
Anne Wagner, Lauren Myers, Andrea Lucie
Catherine Oxenberg's daughter India survived a traumatic experience in the NXIVM cult, leading to long-lasting scars. The Catherine Oxenberg Foundation now supports survivors of sexual assault with ketamine-assisted psychotherapy retreats.
Vicky Dulai, Catherine Oxenberg, India Oxenberg
Psychedelics and 5-HT2A agonists show varying anti-inflammatory effects unrelated to their behavioral impact. Research identifies cellular mechanisms and aims to develop new compounds with targeted therapeutic properties.
Psychedelic compounds show promise for treating neuropsychiatric disorders, but limited patient access is a challenge. Non-hallucinogenic psychedelics, or neuroplastogens, are emerging as a potential solution to address concerns.
Executives of major psychedelic drug developers discuss building infrastructure for psychedelic therapy in healthcare, including education, clinics, EMR tools, and research to enhance outcomes.
Doug Drysdale
Entheogens are being used in traditional Indigenous medicine practices for therapeutic purposes. Indigenous initiatives are creating intercultural clinics to offer entheogen-assisted treatments for substance use disorders and mental health challenges.
Anja Loizaga-Velder
Study investigates psilocybin's effects on depression and burnout in healthcare clinicians post-COVID frontline work with pre- and post-dose psychotherapy. Trial registration: NCT05163496.
Anthony L Back
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.